Clinical Trial

A Study of DXC014 in Patients With Advanced Solid Tumors.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC014 in patients with Advanced Solid Tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-10; most recent amendment 2026-07-02.
Status change: Not Yet Recruiting → Recruiting 2026-04-23
Trial Details
NCT Number NCT07177937
Lead Sponsor Hangzhou DAC Biotechnology Co., Ltd.
Conditions Small Cell Lung Cancer, Melanoma, Prostate Cancer, Other Advanced Solid Tumors
Enrollment 150 participants
Start Date 2026-03-03
Primary Completion 2030-10-20 (estimated)
Study Completion 2030-10-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-06